A dual GLP-1/glucagon agonist showing strong weight loss with preserved lean mass — a unique differentiator.
Pemvidutide (ALT-801) is an investigational dual GLP-1/glucagon receptor agonist developed by Altimmune. Like survodutide, it combines GLP-1-mediated appetite suppression with glucagon-driven energy expenditure and fat oxidation. However, pemvidutide has reported a potentially unique advantage: preservation of lean body mass during weight loss.
A major concern with GLP-1-mediated weight loss is that 30-40% of weight lost may be lean mass (muscle), raising concerns about sarcopenia, especially in older adults. Pemvidutide's Phase 1b data suggested that a higher proportion of weight loss was fat mass compared to GLP-1-only agents — potentially due to the glucagon component's effects on protein metabolism.
If confirmed in larger trials, lean mass preservation would be a significant competitive differentiator in the metabolic drug landscape.
Phase 1b results showed approximately 10% weight loss over 12 weeks. Body composition analysis by DEXA suggested favorable fat-to-lean mass loss ratios compared to historical GLP-1-only data. Phase 2 MOMENTUM trial results showed up to 15.6% weight loss at 48 weeks.
Liver fat reduction was also substantial, supporting potential MASH/NASH applications. The dual mechanism of GLP-1 + glucagon appears to produce complementary metabolic effects beyond either pathway alone.
📚 Key Reference: PMID: 37656085 (pemvidutide Phase 1b)
GI side effects similar to GLP-1 class. Glucagon component could theoretically raise glucose in some patients. Full safety profile pending larger trials.
NOT FDA-approved. In Phase 2 clinical trials.